Keytruda®(pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) – New indication
April 3, 2023 - The FDA announced the approval of Merck’s Keytruda (pembrolizumab) plus Astellas Pharma’s Padcev (enfortumab vedotin-ejfv), for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.
Top